

## Guidelines for the Blood Transfusion Services

### Chapter 22: Haemopoietic progenitor cells

<http://transfusionguidelines.org/red-book/chapter-22-haemopoietic-progenitor-cells>

## Chapter 22:

### Haemopoietic progenitor cells

#### 22.1: Introduction

Cellular therapy is now covered by a variety of legislation. The EU Directive on Tissues and Cells (2004/23/EC) and its associated Commission Directives (2006/17/EC and 2006/86/EC) have been transposed into UK law as the Human Tissue (Quality and Safety for Human Application) Regulations, 2007 as amended. The Human Tissue Act 2004, Human Tissue (Scotland) Act 2006 and Directions or Codes of Practice issued by the Human Tissue Authority also apply. In addition, there are a number of key international standards for haemopoietic stem cells, notably the FACT-JACIE and the NetCord-FACT Standards and the WMDA standards. The lists of publications in sections 22.1.1 and 22.1.2 have been grouped according to their origins.

The guideline references in this chapter apply to the donation, collection, testing, processing, cryopreservation, storage and distribution of haemopoietic progenitor cells (HPC) and mononuclear cells (MNC) within the UK. These guidelines are applicable to stem cell donor registries and to bone marrow, peripheral blood and cord blood collection and processing facilities, and importing facilities, hereafter mentioned as establishments.

#### 22.1.1: UK Regulation/Guidelines

1. Statutory Instrument 2007 No. 1523 The Human Tissue (Quality and Safety for Human Application) Regulations 2007, and subsequent amendments. Available at [www.legislation.gov.uk](http://www.legislation.gov.uk)
2. HTA Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment (current edition), available at [www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance)
3. Human Tissue Act 2004 (except Scotland). Available at [www.legislation.gov.uk](http://www.legislation.gov.uk)
4. Human Tissue (Scotland) Act 2006. Available at [www.show.scot.nhs.uk](http://www.show.scot.nhs.uk)
5. Human Tissue Authority Codes of Practice. Available at [www.hta.gov.uk](http://www.hta.gov.uk)
  1. Guiding principles and the fundamental principle of consent (Code A)
  2. Donation of Allogeneic Bone Marrow and Peripheral Blood Stem Cells for Transplantation (Code G).
6. Human Tissue Authority Guidance document for establishments working with Umbilical cord blood. Available at [www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/establishments-involved-cord-blood](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/establishments-involved-cord-blood)
7. Data Protection Act 2018. Available at [www.gov.uk/data-protection](http://www.gov.uk/data-protection)
8. BSHI Guidelines for HLA matching and donor selection for haematopoietic progenitor cell transplantation. Available at [www.bshi.org.uk](http://www.bshi.org.uk)

9. Joint UKBTS Professional Advisory Committee's (JPAC) Donor Selection Guidelines for either cord blood donors or bone marrow/peripheral blood stem cell donors. Available at [www.transfusionguidelines.org](http://www.transfusionguidelines.org)
10. Joint UKBTS Professional Advisory Committee's (JPAC) Geographical Disease Risk Index (GDRI). Available at: [www.transfusionguidelines.org](http://www.transfusionguidelines.org)
11. Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) Microbiological Safety Guidelines. Available at [www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation](http://www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation)

### 22.1.2: European & International Directives/Guidelines

---

1. EDQM Guide to the quality and safety of tissues and cells for human application. Available at [www.edqm.eu/en/guide-to-the-quality-and-safety-of-tissues-and-cells-for-human-application1](http://www.edqm.eu/en/guide-to-the-quality-and-safety-of-tissues-and-cells-for-human-application1)
2. EC Guidelines to Good Manufacturing Practice (Eudralex) Manufacture of Sterile Medicinal Products. Available at [ec.europa.eu/health/medicinal-products/eudralex\\_en](http://ec.europa.eu/health/medicinal-products/eudralex_en)
3. International Standards for Cellular Therapy Product Collection, Processing, and Administration. From the Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Accreditation Committee of ISCT-Europe and EBMT (JACIE). Available at [www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)
4. International Standards for Cellular Therapy Product Collection, Processing, and Administration Accreditation Manual. Available at [www.jacie.org](http://www.jacie.org)
5. NetCord-FACT International Standards for Cord Blood Collection, Banking and Release for Administration. Available at [www.factwebsite.org](http://www.factwebsite.org)
6. NetCord-FACT Cord Blood Accreditation Manual. Available at [www.factweb.org/forms/store/CommercePlusFormPublic/search?action=Publications](http://www.factweb.org/forms/store/CommercePlusFormPublic/search?action=Publications)
7. World Marrow Donor Association (WMDA) International Standards for Unrelated Haematopoietic Stem Cell Donor Registries - promotes a range of standards, guidelines and recommendations to facilitate the exchange of haematopoietic stem cells across international borders. Available at [www.wmda.info](http://www.wmda.info)
8. European Federation for Immunogenetics (EFI) 'Standards for histocompatibility testing'. Available at [efi-web.org](http://efi-web.org)
9. National Marrow Donor Program (USA) Standards. May be helpful in benchmarking for equivalent UK standards. Available at [www.marrow.org](http://www.marrow.org)
10. WMDA Donor Medical Suitability Recommendations. Available at [share.wmda.info/display/DMSR/WMDA+Donor+Medical+Suitability+Recommendations+Main+page](http://share.wmda.info/display/DMSR/WMDA+Donor+Medical+Suitability+Recommendations+Main+page)

## 22.2: Terminology

---

This chapter aligns with the terminology described at FACT-JACIE International Standards for Haemopoietic Cellular Therapy, Product Collection, Processing, and Administration, as below.

[www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)

## 22.3: Policy and procedure requirements and Safety

---

### 22.3.1: HTA licensing and requirements

The procurement and testing of human tissues or cells in UK should only be carried out by establishments holding an appropriate HTA licence or by individuals or organisations working under the authority of a third-party agreement with an establishment holding an appropriate HTA licence.

The below requirements apply to the establishments and third parties which carry out the procurement, testing, processing, distribution, or export of tissues and cells for human application, and for licensed establishments which store or import tissues and cells for human application.

[www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance)

---

### **22.3.2: FACT-JACIE and NetCord-FACT standards**

The FACT-JACIE and NetCord-FACT standards are available for the clinical and laboratory facilities who wish to conform to the FACT-JACIE and NetCord-FACT Standards as appropriate.

[www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)

---

## **22.4: Adverse events and reactions**

---

### **22.4.1: HTA Guide for the management of serious adverse events (SAEs) and reactions (SARs)**

All licensed establishments must have a system in place for reporting, investigating, registering and recording information about SAEs and SARs which may influence the quality and safety of tissues and cells, and which may be associated with any licensable activity, as well as any SAR observed during or after clinical application which may be linked to the quality and safety of tissues and cells.

[www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance)

---

### **22.4.2: WMDA reporting system**

WMDA maintains a voluntary central global reporting system to report Serious (Product) Events and Adverse Reactions – S(P)EARs as below

<https://spear.wmda.info/>

---

## **22.5: Donor selection, consent and testing**

Establishments must have detailed policies and procedures for the testing and assessment of donors of stem cells. These must be in accordance with the requirements of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended), UK-JPAC standards, FACT-JACIE Standards and the WMDA standards.

Anonymity must be maintained between donors and recipients in accordance with the requirements of EU Directive 2004/23/EC (Northern Ireland) and the UK information governance regulations.

[www.transfusionguidelines.org/dsg/bm](http://www.transfusionguidelines.org/dsg/bm)

[share.wmda.info/display/DMSR/WMDA+Donor+Medical+Suitability+Recommendations+Main+page](http://share.wmda.info/display/DMSR/WMDA+Donor+Medical+Suitability+Recommendations+Main+page)

[www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)

[fact.policytech.com/dotNet/documents/?docid=534&public=true](http://fact.policytech.com/dotNet/documents/?docid=534&public=true)

<http://data.europa.eu/eli/dir/2004/23/oj>

## 22.6: Collection, processing and storage

---

Stem Cells and Therapeutic Cells should only be collected in a hospital facility or Blood Service apheresis unit with appropriate experience (see section 5.8) and which meets the standards required by the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended), FACT-JACIE Standards and NetCord-FACT Standards as appropriate.

HTA Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment

[www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/human-application/hta-guide-quality-and-safety-assurance)

FACT-JACIE Standards Parts CM, C and D

[www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)

## 22.7: Testing of haemopoietic progenitor cell donors and components

---

Infectious disease marker testing, ABO and RhD typing and clonogenic assays must be done in accordance with the HTA guide to quality and safety assurance for tissues and cells for patient treatments -updated on January 2021, and the SaBTO guidance.

Additional information and guidance available with FACT-JACIE, WMDA and NetCord-FACT standards.

The minimum current requirements for mandatory and additional microbiology testing (serology and/or NAT) are described in Chapter 9.

Annex 7 indicates the requirements for the timing of testing for each type of HPC.

## 22.8: Requirements for the timing of testing

---

Please see Annex 7 for guidance relating to the timing of testing for different categories of HPC.

## 22.9: Labelling, packaging, transportation and release

---

The mandatory requirements for these are described in the HTA's Guide to Quality and Safety Assurance for Human Tissue and Cells for Patient Treatment.

The FACT-JACIE Standards and NetCord-FACT Standards will also apply as appropriate.

The requirement for an EU Single European Code (SEC) still applies in Northern Ireland.

[health.ec.europa.eu/blood-tissues-cells-and-organs/implementation/single-european-code-sec-tissues-and-cells\\_en#:~:text=The%20%22Single%20European%20Code%E2%80%9D%20or,type%20of%20tissue%20or%20cells](https://health.ec.europa.eu/blood-tissues-cells-and-organs/implementation/single-european-code-sec-tissues-and-cells_en#:~:text=The%20%22Single%20European%20Code%E2%80%9D%20or,type%20of%20tissue%20or%20cells)

## 22.10: Disposal of haemopoietic progenitor cells

---

Disposal of cellular therapy products shall include the following requirements shall meet the EBMT guideline requirements (Chapter D12: Disposal)

[www.ebmt.org/accreditation/jacie-standards](http://www.ebmt.org/accreditation/jacie-standards)

## 22.11: Record Maintenance

---

All patient records and results should be maintained to comply the requirements of the GDPR.

[ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/accountability-and-governance/documentation](https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/accountability-and-governance/documentation)

Establishments must comply with SaBTO advice in record keeping and maintenance.

[www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation](https://www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation)

The requirements for these are described in the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended), FACT-JACIE Standards, NetCord-FACT Standards and WMDA standards as above.